← Back to Clinical Trials
Recruiting NCT05093881

Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Alcoholic Cirrhosis
Sponsor Pharmicell Co., Ltd.
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2021-08-24
Completion 2026-08-24
Interventions
Cellgram-LC

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Eligibility Criteria

Inclusion Criteria: 1. Those who participated in PMC-P-07 clinical trials and received Cellgram-LC 2. Those who voluntarily agreed in writing to participate in this investigation Exclusion Criteria: \-

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE ALCOHOLIC CIRRHOSIS TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}